Takeda Pharmaceutical Co. Ltd. has reached an agreement to acquire Nycomed for $13.7 billion on a cash-free, debt-free basis. The transaction, subject to antitrust clearance, is expected to be completed within 90 to 120 days, making it a wholly owned subsidiary of Takeda. The purchase would exclude Nycomed’s U.S. dermatology business. Nycomed, headquartered in Zurich, Switzerland, has a diversified product portfolio of both established prescription and OTC products. Its significant busi...